DiaMedica Therapeutics Inc

Research DiaMedica Therapeutics Inc (DMAC) on Bullrun: market cap USD 389.04M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerDMAC
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 389.04M
• Financial periodFY2025
• Net income-USD 32.77M
• Free cash flow-USD 29.10M

Valuation Snapshot

latest market cap is USD 389.04M.

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

Frequently asked questions

What is DiaMedica Therapeutics Inc's market cap?

DiaMedica Therapeutics Inc's market capitalization is USD 389.04M.

What does DiaMedica Therapeutics Inc do?

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.